natgillin/translations-raw huggingface dataset:
• Dosing is based on your baby's weight following the scheme below: Weeks (daily dose)
• Odmerek temelji na telesni masi vašega dojenčka, pri čemer se upošteva spodnja shema:
HEMANGIOL 3.75 mg/mL oral solution propranolol
HEMANGIOL 3,75 mg/ml peroralna raztopina propranolol
If your child is not eating, develops another illness or is vomiting, it is recommended to skip the dose.
Če otrok ne je, zboli za dodatno boleznijo ali bruha, priporočamo, da preskočite odmerek.
• Decreased blood pressure.
• znižan krvni tlak,
Propranolol is metabolised in the liver and excreted by the kidneys.
Propranolol presnavljajo jetra, izločajo pa ga ledvice.
Skip the missed dose, and do not give a double dose to make up for a forgotten dose.
Če ste pozabili dati otroku zdravilo HEMANGIOL Preskočite pozabljeni odmerek in ne dajajte dvojnega odmerka, če ste pozabili dati prejšnji odmerek.
Risks of hypoglycaemia
Tveganje za hipoglikemijo
• If you have any further questions, ask your doctor, or pharmacist or nurse.
• Če imate dodatna vprašanja, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Only use the oral syringe that is supplied with the medicine to measure and administer the dose.
Za merjenje in dajanje odmerka uporabljajte le peroralno brizgo, ki je priložena zdravilu.
The carton contains the following items that you will need to administer the medicine: - The glass bottle containing 120 mL propranolol oral solution - The oral syringe graduated in mg provided with this medicine Remove the bottle and oral syringe from the box and remove the syringe from the plastic bag.
- steklenica, ki vsebuje 120 ml peroralne raztopine propranolola - peroralna brizga, umerjena v mg, priložena zdravilu Vzemite steklenico in peroralno brizgo iz škatle in vzemite brizgo iz plastične vrečke.
Antihypertensives (ACE Inhibitors, angiotensin II-receptors antagonists, diuretics, alpha-blockers whatever the indication, centrally-acting antihypertensives, reserpine, etc) When combined with beta-blockers, medicinal products that decrease arterial pressure can cause or increase hypotension, notably orthostatic.
Antihipertenzivi (zaviralci ACE, antagonisti angiotenzinskih receptorjev tipa II, diuretiki, antagonisti adrenergičnih receptorjev alfa pri kateri koli indikaciji, centralno delujoči antihipertenzivi, rezerpin,
With the oral syringe in place, turn the bottle upside down.
Z nastavljeno peroralno brizgo obrnite steklenico na glavo.
The following table gives the adverse reactions, reported whatever dose and treatment duration, in three clinical studies, including 435 patients treated by HEMANGIOL at 1 mg/kg/day or 3 mg/kg/day for a maximum treatment duration of 6 months.
Naslednja tabela navaja neželene učinke glede na odmerek in trajanje zdravljenja iz treh kliničnih študij, ki so vključevale 435 bolnikov, zdravljenih z zdravilom HEMANGIOL z odmerkom
It is recommended to increase the dose up to the therapeutic dose under medical supervision as follows: 1 mg/kg/day for 1 week, then 2 mg/kg/day for 1 week and then 3 mg/kg/day as a maintenance dose.
1 teden 1 mg/kg/dan, nato 1 teden 2 mg/kg/dan in nato 3 mg/kg/dan kot vzdrževalni odmerek.
This is because your child can get low blood pressure if given certain anaesthetics while taking this medicine (see “Other medicines and HEMANGIOL”).
To storite zaradi tega, ker lahko pride do nizkega krvnega tlaka, če otrok prejme določene anestetike med jemanjem tega zdravila
Or
Ali
• If your child is not eating or is vomiting it is recommended to skip the dose.
• Če otrok ne je ali če bruha, priporočamo, da preskočite odmerek.
• Infants prone to hypoglycaemia
• Dojenčki, nagnjeni k hipoglikemiji
Decreased blood glucose
Znižan krvni tlak Znižana glukoza v krvi
• Minor: pallor, tiredness, sweating, shaking, palpitations, anxiety, hunger, difficulty waking up.
• manjši: bledica, utrujenost, potenje, tresenje, palpitacije (razbijanje srca), tesnobnost, lakota,
If the child is not eating or is vomiting it is recommended to skip the dose.
Če otrok ne je, ali pa bruha, priporočamo, da preskočite odmerek.
• Moreover, if you are breastfeeding your child, it is important to tell your doctor, pharmacist or nurse which medicines you are yourself taking, as they may pass into your breast-milk and interfere with the treatment of your child.
katera zdravila jemljete sami, saj lahko preidejo v vaše mleko in motijo zdravljenje vašega otroka.
Neutropenia
Bruhanje
• Medicines used for anaesthesia.
• zdravila, ki se uporabljajo za znižanje ravni maščob v krvi, • zdravila, ki se uporabljajo za anestezijo.
Decreased appetite
Zmanjšan tek
HEMANGIOL 3.75 mg/mL oral solution
HEMANGIOL 3,75 mg/ml peroralna raztopina
• Diarrhoea and vomiting.
• driska in bruhanje.
5 PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties
5.1 Farmakodinamične lastnosti
1 ml of solution contains 4.28 mg of propranolol hydrochloride equivalent to 3.75 mg of propranolol base.
1 ml raztopine vsebuje 4,28 mg propranololijevega klorida, kar je enakovredno 3,75 mg propranolola.
'phaeochromocytoma'.
To se imenuje »feokromocitom«.
Beta stimulating agents may be used to counteract the beta-blockade.
Zdravila z betaadrenergičnim stimulativnim učinkom se lahko uporabljajo za preprečevanje učinkov antagonistov adrenergičnih receptorjev beta.
Worsening of disease has been reported with beta-blockers in patients suffering from psoriasis.
Razpoložljiva literatura navaja, da beta-blokatorji spadajo med zdravila, ki so najbolj povezana s psoriazo pri odraslih.
Use with oral syringe graduated in mg of propranolol included in the package.
POSTOPEK IN POT(I) UPORABE ZDRAVILA Uporabite z graduirano brizgo za peroralno dajanje, umerjeno v mg propranolola, ki je priložena v pakiranju.
Atrioventricular blocks, intraventricular conduction delays, and congestive heart failure can occur with more severe poisoning.
Pri hujši zastrupitvi lahko pride do atrioventrikularnih blokov, zamikov intraventrikularnega prevajanja in kongestivnega srčnega popuščanja.
1 ml of solution contains 4.28 mg of propranolol hydrochloride equivent to 3.75 mg of propranolol.
1 ml raztopine vsebuje 4,28 mg propranololijevega klorida, kar ustreza 3,75 mg propranolola.
The active ingredient is propranolol.
Učinkovina je propranolol.
Each ml contains 4.28 mg of propranolol hydrochloride equivalent to 3.75 mg of propranolol.
En ml vsebuje 4,28 mg propranololijevega klorida, kar je enakovredno 3,75 mg/ml propranolola.
Diarrhea Vomiting
Žilne bolezni
Combinations should consider the 2 following situations (not mutually exclusive):
Pri kombiniranju zdravil je treba upoštevati naslednji dve situaciji (med seboj se ne izključujeta): • dojenčki, ki prejemajo kakršna koli druga zdravila, predvsem spodaj omenjena.
HEMANGIOL may be stopped at once at the end of the treatment as decided by the doctor.
Če ste prenehali dajati otroku zdravilo HEMANGIOL Zdravilo HEMANGIOL lahko prenehate dajati takoj po končanem zdravljenju, če tako določi zdravnik.
Open the bottle
• 3. korak: Odprite steklenico
• If your child get any side effects, talk to your doctor or pharmacist or nurse.
• Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Instructions for use: • Step 1.
Navodila za uporabo:
This medicine will not be recommended in case of liver or kidneys impairment.
V primeru motenj delovanja jeter ali ledvic to zdravilo ne bo priporočeno.
Hyperkalaemia has been reported in the literature in few patients with large ulcerated haemangioma (see section 4.4).
O hiperkaliemiji so poročali v dokumentaciji pri nekaj bolnikih z velikim ulceriranim hemangiomom
Package leaflet: Information for the user HEMANGIOL 3.75 mg/mL oral solution propranolol
Navodilo za uporabo HEMANGIOL 3,75 mg/ml peroralna raztopina propranolol
Insert the syringe into your baby's mouth and place it against the inside of the cheek.
• 9. korak Dajanje zdravila HEMANGIOL otroku Vstavite brizgo v dojenčkova usta in jo pritisnite ob notranji del lica.
Antiarrhythmics
Antiaritmiki
Decreased blood pressure
• nizek krvni tlak
• Hypoglycemia may develop and manifestations of hypoglycemia (tremor, tachycardia) may be masked by other clinical effects of beta-blocker toxicity.
• Zaradi drugih kliničnih učinkov toksičnosti antagonistov adrenergičnih receptorjev beta lahko pride do hipoglikemije in zakritja manifestacij hipoglikemije (tresavice, tahikardije).
Store the bottle and oral syringe in the outer carton between each use.
Steklenico in peroralno brizgo shranite v škatli do naslednje uporabe.
• Very low levels of white blood cells that fight infection
• zelo nizke ravni belih krvnih celic, ki se borijo z okužbo, • težave s krvnim obtokom, zaradi katerih postanejo prsti na nogah in rokah otrpli in bledi,
Hypoglycemic seizure
Hipoglikemična sredstva
The effects generally totally reversed after treatment cessation.
Po prekinitvi zdravljenja so se učinki na splošno popolnoma vrnili v prvotno stanje.
Risk of hyperkaliemia
Agranulocitoza Hiperkaliemija
Give HEMANGIOL to your child
Kako otroku dajati zdravilo HEMANGIOL
Erythema Dermatitis diaper
Dermatitis pod plenico
This leaflet was last revised in. Other sources of information
Navodilo je bilo nazadnje revidirano dne
Lipid lowering medicinal products
NAČIN IZDAJANJA ZDRAVILA
CARTON BOX / BOTTLES NAME OF THE MEDICINAL PRODUCT
PODATKI NA ZUNANJI OVOJNINI IN PRIMARNI OVOJNINI KARTONSKA ŠKATLA/STEKLENICE
proliferation.
Odmerjanje
Sleep disorder
težave pri prebujanju.
General anaesthesia
Splošna anestezija
Respiratory disorders
Srčne bolezni
DO NOT GIVE HEMANGIOL TO YOUR CHILD UNTIL HE IS BEING CORRECTLY FED AGAIN.
OTROKU NE DAJAJTE ZDRAVILA HEMANGIOL, DOKLER NI ZNOVA USTREZNO NAHRANJEN.
Batch
Odmerek
This summary was last updated in 06-2015.
Povzetek je bil nazadnje posodobljen 06-2015.
It is available as tablets (75 mg).
Na voljo je v obliki tablet (75 mg).
In acute coronary syndrome and atrial fibrillation, Clopidogrel HCS is used together with aspirin, the dose of which should not be higher than 100 mg.
Pri akutnem koronarnem sindromu in atrijski fibrilaciji se zdravilo Clopidogrel HCS uporablja skupaj z aspirinom, katerega odmerek ne sme biti višji od 100 mg.
The European Commission granted a marketing authorisation valid throughout the European Union for Clopidogrel HCS on 28 October 2010.
Evropska komisija je dovoljenje za promet z zdravilom Clopidogrel HCS, veljavno po vsej Evropski uniji, izdala 28. oktobra 2010.
This is a summary of the European public assessment report (EPAR) for Clopidogrel HCS.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Clopidogrel HCS.
Clopidogrel HCS is used in adults to prevent problems caused by blood clots.
Zdravilo Clopidogrel HCS se uporablja pri odraslih za preprečevanje težav, ki jih povzročajo krvni strdki.
The standard dose of Clopidogrel HCS is one 75-mg tablet once a day.
Običajni odmerek zdravila Clopidogrel HCS je ena 75-miligramska tableta enkrat dnevno.
In acute coronary syndrome, treatment generally starts with a loading dose of four tablets.
Pri akutnem koronarnem sindromu se zdravljenje načeloma uvede z udarnim odmerkom štirih tablet.
This means that Clopidogrel HCS is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
To pomeni, da je podobno referenčnemu zdravilu, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Plavix.
This stops the platelets becoming ‘sticky', reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke.
To preprečuje, da bi trombociti postali lepljivi, ter tako zmanjšuje tveganje za nastanek krvnih strdkov in prispeva k preprečitvi novega srčnega napada ali kapi.
For more information about treatment with Clopidogrel HCS, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Clopidogrel HCS preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
This is then followed by the standard 75mg dose once a day for at least four weeks (in ST segment elevation myocardial infarction) or for up to 12 months (in unstable angina or non-Q-wave myocardial infarction).
Temu sledi običajni 75-miligramski odmerek enkrat na dan za najmanj štiri tedne (pri miokardnem infarktu z elevacijo spojnice ST) ali največ 12 mesecev (pri nestabilni angini pektoris ali pri miokardnem infarktu brez zobca Q).
It is used in patients who have at least one risk factor for events such as a heart attack or stroke, cannot take vitamin-K antagonists (other medicines that prevent blood clots) and are at low risk of bleeding.
Uporablja se pri bolnikih, ki imajo vsaj en dejavnik tveganja za dogodke, kot so srčni napad ali kap, ki ne smejo jemati antagonistov vitamina K (drugih zdravil, ki preprečujejo krvne strdke) in pri katerih je tveganje za krvavitve majhno.
The full EPAR for Clopidogrel HCS can be found on the Agency's website: EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Clopidogrel HCS je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Clopidogrel HCS can be started between a few days and 35 days after the attack;
Zdravilo se lahko začne jemati nekaj dni po napadu do 35 dni po njem;
Because Clopidogrel HCS is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as those of the reference medicine's.
Ker je zdravilo Clopidogrel HCS generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
Clopidogrel HCS can be used in patients who are having a heart attack with ‘ST segment elevation' (an abnormal reading on the ECG or electrocardiogram) when the doctor thinks that they would benefit from the treatment.
Zdravilo Clopidogrel HCS se lahko uporablja pri bolnikih, ki so doživeli srčni napad z elevacijo spojnice ST (nenormalnim zapisom na EKG ali elektrokardiogramu), če zdravnik meni, da bi jim zdravilo pomagalo.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel HCS.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Clopidogrel HCS, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What are the benefits and risks of Clopidogrel HCS?
Kakšne so koristi in tveganja, povezana z zdravilom Clopidogrel HCS?
Clopidogrel HCS can be given to the following groups of patients:
Zdravilo se lahko daje naslednjim skupinam bolnikov:
• patients with acute coronary syndrome (a condition in which blood supply to the heart is reduced), when it should be given with aspirin (another medicine that prevents blood clots), including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up).
• bolnikom z akutnim koronarnim sindromom (bolezenskim stanjem, za katerega je značilen zmanjšan dotok krvi v srce) , pri katerih se mora zdravilo dajati skupaj z aspirinom (drugim zdravilom za preprečevanje krvnih strdkov), vključno z bolniki, ki jim je bil vstavljen stent (kratka cevka, nameščena v arteriji, da prepreči njeno zamašitev).
The Committee recommended that Clopidogrel HCS be given marketing authorisation.
Odbor je zato priporočil, da se za zdravilo Clopidogrel HCS izda dovoljenje za promet.
It can also be used in patients who do not have this abnormal reading on the ECG, if they have unstable angina (a severe type of chest pain) or have had a ‘non-Q-wave' myocardial infarction.
Lahko se uporablja tudi pri bolnikih, ki nimajo nenormalnega zapisa na EKG, če imajo nestabilno angino pektoris (hudo obliko bolečine v prsih) ali so doživeli miokardni infarkt brez zobca Q.
Because Clopidogrel HCS is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Ker je zdravilo Clopidogrel HCS generično zdravilo, so bile študije pri ljudeh omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Plavix.
• patients with atrial fibrillation (irregular rapid contractions of the upper chambers of the heart), when it should be given with aspirin.
• bolnikom z atrijsko fibrilacijo (nerednim hitrim krčenjem srčnih preddvorov), pri katerih se mora dajati skupaj z aspirinom.
The CHMP concluded that, in accordance with EU requirements, Clopidogrel HCS has been shown to have comparable quality and to be bioequivalent to Plavix.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Clopidogrel HCS primerljivo raven kakovosti kot zdravilo Plavix ter da mu je biološko enakovredno.
Therefore, the CHMP's view was that, as for Plavix, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Plavix, odtehtajo znana tveganja.
Clopidogrel HCS can be started between seven days and six months after the stroke;
Zdravilo se lahko začne jemati od sedem dni po kapi do šest mesecev po njej;
• patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain).
• bolnikom, ki so nedavno doživeli ishemično kap (kap, ki jo povzroči prekinitev dotoka krvi v del možganov).
Clopidogrel HCS is a blood-thinning medicine that contains the active substance clopidogrel.
Clopidogrel HCS je zdravilo, ki vsebuje zdravilno učinkovino klopidogrel.
The active substance in Clopidogrel HCS, clopidogrel, is an inhibitor of platelet aggregation.
Zdravilna učinkovina v zdravilu Clopidogrel HCS, klopidogrel, je zaviralec agregacije trombocitov.
Other information about Clopidogrel HCS
Druge informacije o zdravilu Clopidogrel HCS
Clopidogrel HCS is a ‘generic medicine'.
Zdravilo Clopidogrel HCS je generično zdravilo.
Why has Clopidogrel HCS been approved?
Zakaj je bilo zdravilo Clopidogrel HCS odobreno?
What is Clopidogrel HCS?
Kaj je zdravilo Clopidogrel HCS?
What is Clopidogrel HCS used for?
Za kaj se zdravilo Clopidogrel HCS uporablja?
How has Clopidogrel HCS been studied?
Kako je bilo zdravilo Clopidogrel HCS raziskano?
How does Clopidogrel HCS work?
Kako zdravilo Clopidogrel HCS deluje?
How is Clopidogrel HCS used?
Kako se zdravilo Clopidogrel HCS uporablja?
List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states for tetrazepam-containing medicinal product(s)
PRILOGA I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVIL, POTI UPORABE, IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
Luxembourg Will Pharma S.A. Monplaisirlaan 33
Luksemburg Will Pharma S.A. Monplaisirlaan 33
Luxembourg Eurogenerics NV Heizel Esplanade b22
Luksemburg Eurogenerics NV Heizel Esplanade b22
Luxembourg Sanofi Aventis Belgium N.V Culliganlaan 1C
Luksemburg Sanofi Aventis Belgium N.V Culliganlaan 1C
ratiopharm GmbH Graf-Arco-Str. 3 89079 Ulm Germany
Poljska ratiopharm GmbH Graf-Arco-Str. 3 89079 Ulm Germany
Tetrazepamratiopharm 50 mg Filmtabletten
Tetrazepam-ratiopharm 50 mg Filmtabletten
22 October 2009
20. april 2011
Why were these medicines reviewed?
Zakaj so bila ta zdravila pregledana?
See: http://www.who.int/cancer/palliative/painladder/en/.
Glejte: http://www.who.int/cancer/palliative/painladder/en/.
Some information was also available from studies in human volunteers.
Nekaj informacij je bilo na voljo tudi iz študij pri prostovoljcih.
These are called ‘controlled-release systems'.
Te se imenujejo „sistemi za nadzorovano sproščanje“.
They should take note of the restrictions and warnings for the medicines that they are using.
Upoštevati morajo omejitve in opozorila za zdravila, ki jih uporabljajo.
• Patients who have any questions should speak to their doctor or pharmacist.
• Bolniki, ki imajo kakršna koli vprašanja, naj se posvetujejo z zdravnikom ali farmacevtom.
Which data has the CHMP reviewed?
Katere podatke je pregledal CHMP?
These included patients with late-stage cancer.
Te so vključevale bolnike z rakom v poznem stadiju.
What are the recommendations for patients and prescribers?
Kakšna so priporočila za bolnike in zdravnike, ki predpisujejo zdravila?
The full changes made to the information to doctors and patients are detailed here.
Vse spremembe v informacijah za zdravnike in bolnike so na voljo tukaj.
They looked at seven different systems used with morphine, two used with hydromorphone and four used with oxycodone.
Pregledali so sedem različnih sistemov, ki so se uporabljali z morfinom, dva s hidromorfonom in štiri z oksikodonom.
When these capsules were put into a 20% alcohol solution, 80% of the active substance was released within 15 minutes.
Ko so te kapsule položili v 20-odstotno raztopino alkohola, se je 80 % zdravilne učinkovine sprostilo v 15 minutah.
This means that almost a full day's dose of morphine would be released all at once if a patient were to take the capsule with large drink of neat strong liquor, such as whisky or vodka.
To pomeni, da bi se naenkrat sprostil skoraj celodnevni odmerek morfina, če bi bolnik kapsulo vzel z večjo količino močne alkoholne pijače, na primer viskijem ali vodko.
‘Modified-release' forms of these medicines release the active substance slowly, often over many hours.
Oblika teh zdravil s „prirejenim sproščanjem“ sprošča zdravilno učinkovino počasi, pogosto več ur.
Therefore, the Committee recommended that the warnings on this interaction be made consistent in the information for doctors and patients across all oral opioid medicines of the WHO level III scale.
Odbor je zato priporočil, da se opozorila o tem medsebojnem delovanju dosledno navedejo v informacijah za zdravnike in bolnike za vsa peroralna opioidna zdravila III. stopnje po lestvici SZO.
There are over 500 different medicines belonging to the WHO level III scale group authorised in European Union (EU) Member States.
V državah članicah Evropske unije (EU) je odobrenih več kot 500 različnih zdravil iz skupine zdravil III. stopnje po lestvici SZO.
The CHMP noted that the use of this medicine in combination with alcohol is already contra-indicated.
CHMP je ugotovil, da je uporaba tega zdravila v kombinaciji z alkoholom že kontraindicirana.
For all other medicines in this class, the Committee concluded that their benefits continue to outweigh their risks, and therefore recommended that their marketing authorisations be maintained.
Za vsa druga zdravila v tej skupini je Odbor sklenil, da njihove koristi še vedno odtehtajo z njimi povezana tveganja in zato priporočil, da se dovoljenja za promet s temi zdravili ohranijo.
They include morphine and the related medicines oxycodone and hydromorphone, all of which work by attaching to receptors in the brain and spinal cord to prevent pain.
Vključujejo morfin ter sorodni zdravili oksikodon in hidromorfon, ki delujejo tako, da se vežejo na receptorje v možganih in hrbtenjači ter tako preprečujejo bolečino.
Consequently, the European Commission asked the CHMP to carry out an assessment of the benefitrisk balance of these medicines, concentrating on their interaction with alcohol, and to issue an opinion on whether their marketing authorisations should be maintained, varied, suspended or withdrawn across the EU.
Zato je Evropska komisija CHMP zaprosila, da izvede oceno razmerja med tveganji in koristmi teh zdravil s poudarkom na medsebojnem delovanju z alkoholom in da izda mnenje, ali naj se dovoljenja za promet z zdravili po vsej EU ohranijo, spremenijo, začasno umaknejo ali ukinejo.
• Prescribers are reminded that there are a large number of modified-release opioids available in each Member State.
• Zdravnike, ki predpisujejo zdravila, je treba opomniti, da je v vsaki državi članici na voljo veliko število opioidov s prirejenim sproščanjem.